Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Croda International Plc (49GP.L)
Goole, GB
Croda International Plc, founded in 1925 and based in Goole, UK, is a global enterprise dedicated to the innovation, production, and distribution of specialty chemicals. Its extensive reach covers Europe, the Middle East, Africa, North America, Asia, and Latin America, with operations segmented into Consumer Care, Life Sciences, Performance Technologies, and Industrial Chemicals. The company offers a vast portfolio of products serving diverse industries. This includes specialized ingredients for personal care items like skin, hair, sun, and oral hygiene, as well as cosmetics, deodorants, and men's grooming. In the agricultural sector, Croda supplies additives for crop protection, seed enhancement, and animal health, alongside bio-stimulants. For automotive and industrial applications, its offerings range from lubricant additives, coatings, and polymers to vehicle cleaning chemicals and specialty additives for plastics, batteries, and catalysts. Additionally, Croda provides solutions for construction chemicals, dietary supplements, active pharmaceutical ingredients, and advanced materials for electronics and devices. Other key product areas encompass food additives, specialty polymer additives for furniture, household and industrial cleaning products, oleochemicals, paints and coatings, and materials for packaging, print, and paper industries. A significant focus is on its bio-based phase change materials, engineered for thermal management in applications such as buildings, healthcare, electronics, food refrigeration, temperature-controlled packaging, and vehicles.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.58% | +8,915.54% | +8,030.84% | +7,955.56% | +8,346.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Chemicals - Specialty: +4.7%+4.4% Q4'25: +3.7% (vs Q4'23)
-
EPS growth Chemicals - Specialty: +13.2%-61.4% Q4'25: -99.1% (vs Q4'23)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+11.8% Q4'25: +16.4% (vs Q4'23)
-
EBIT margin Chemicals - Specialty: +8.8%+14.3% ★ Q4'25: +13.6% (vs Q4'23)
-
ROIC Chemicals - Specialty: +5.6%+6.4% ★ Q4'25: +10.1% (vs Q4'23)
-
Share dilution Chemicals - Specialty: +0.1%0.0% Q4'25: +2.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.83× Q4'25: 0.96× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 1 EPS Ana. |
Dec 2027 13 Rev. Ana. 1 EPS Ana. |
Dec 2028 8 Rev. Ana. 1 EPS Ana. |
Dec 2029 12 Rev. Ana. 1 EPS Ana. |
Dec 2030 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.69B
est: 1.71B (-1.0%)
|
1.63B
est: 1.64B (-0.5%)
|
1.70B
est: 1.68B (+0.9%)
|
1.77B
1.72B – 1.84B
+5.0% YoY
|
1.85B
1.81B – 1.94B
+4.5% YoY
|
1.93B
1.88B – 2.02B
+4.5% YoY
|
2.04B
1.99B – 2.13B
+5.6% YoY
|
2.13B
2.08B – 2.23B
+4.7% YoY
|
| EBITDA |
388.50M
est: 499.09M (-22.2%)
|
374.50M
est: 463.59M (-19.2%)
|
380.70M
est: 477.17M (-20.2%)
|
500.97M
488.75M – 520.07M
+5.0% YoY
|
523.26M
511.55M – 550.72M
+4.5% YoY
|
546.74M
533.96M – 571.60M
+4.5% YoY
|
577.31M
563.82M – 603.56M
+5.6% YoY
|
604.65M
590.52M – 632.14M
+4.7% YoY
|
| EBIT |
262.20M
est: 384.65M (-31.8%)
|
238.70M
est: 347.02M (-31.2%)
|
243.70M
est: 357.18M (-31.8%)
|
375.00M
365.85M – 389.30M
+5.0% YoY
|
391.69M
382.92M – 412.24M
+4.5% YoY
|
409.26M
399.70M – 427.87M
+4.5% YoY
|
432.14M
422.04M – 451.79M
+5.6% YoY
|
452.61M
442.03M – 473.18M
+4.7% YoY
|
| Net Income |
171.00M
est: 223.38M (-23.4%)
|
158.50M
est: 190.25M (-16.7%)
|
62.00M
est: 197.60M (-68.6%)
|
219.19M
212.53M – 232.14M
+10.9% YoY
|
247.26M
239.75M – 261.88M
+12.8% YoY
|
271.71M
263.45M – 287.77M
+9.9% YoY
|
303.97M
294.73M – 321.93M
+11.9% YoY
|
318.38M
308.71M – 337.20M
+4.7% YoY
|
| SGA |
482.50M
est: 467.33M (+3.2%)
|
506.40M
est: 433.61M (+16.8%)
|
349.10M
est: 446.31M (-21.8%)
|
468.57M
457.14M – 486.43M
+5.0% YoY
|
489.42M
478.46M – 515.11M
+4.5% YoY
|
511.38M
499.43M – 534.63M
+4.5% YoY
|
539.97M
527.35M – 564.52M
+5.6% YoY
|
565.54M
552.32M – 591.25M
+4.7% YoY
|
| EPS |
1.22
est: 1.60 (-23.7%)
|
1.14
est: 1.36 (-16.3%)
|
0.44
est: 1.42 (-68.9%)
|
1.57
1.52 – 1.66
+10.9% YoY
|
1.77
1.72 – 1.88
+12.8% YoY
|
1.95
1.89 – 2.06
+9.9% YoY
|
2.18
2.11 – 2.31
+11.9% YoY
|
2.28
2.21 – 2.41
+4.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen Edward Foots | Group Chief Executive & Executive Director | 2M | male |
| Stephen Richard Oxley | Chief Financial Officer & Executive Director | 918.7K | male |
| Michelle Fargen | Global Head of Procurement and Sustainable Sourcing | — | — |
| Michelle Lydon | President of Human Resources | — | female |
| Philip Ruxton | Chief Sustainability Officer | — | male |
| Sandra Elaine Breene | President of Consumer Care | — | female |
| Stephen W. Burgess | Managing Director of Nucleic Acid Delivery | — | — |
| Thiru Selvan | President of Supply Chain Operations | — | male |
| Thomas Michael Brophy | Group General Counsel, Company Secretary & President Sustainability | — | male |
| Anthony Damien Fitzpatrick | President of Strategy, Corporate Development & Industrial Specialties | — | male |
| Thomas Riemeier | President of Life Sciences | — | male |
| David Bishop | Director of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 49GP.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
